Compound profile
Melanotan II
Limited human dataAlso known as: MT-II · Melanotan-2
A non-selective melanocortin-receptor agonist originally studied for skin tanning and erectile dysfunction, whose sexual-desire side effects led directly to the development of the FDA-approved drug bremelanotide (PT-141). Widely sold gray-market for tanning despite no approval for that use.
Overview
Melanotan II is a synthetic cyclic peptide built from seven amino acids joined in a closed ring, designed as an analogue of alpha-melanocyte-stimulating hormone, or alpha-MSH, the natural hormone that triggers melanin production in skin cells. It was developed at the University of Arizona in the 1980s by researchers Mac Hadley and Victor Hruby, whose goal was not a cosmetic tanning product but a pharmacologic tool to study the melanocortin receptor system, with an eye toward reducing skin cancer risk by inducing protective tanning without UV exposure.
Structurally it is described as Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-alpha-MSH(4-10)-NH2, a cyclic lactam analogue that activates melanocortin receptors broadly rather than selectively, meaning it engages MC1R, the receptor responsible for pigmentation, alongside MC3R and MC4R, receptors active in the central nervous system that influence appetite, energy balance, and sexual function. That non-selective activity is what led to Melanotan II's most consequential scientific legacy: early human testing revealed it reliably produced erections and increased sexual desire in male subjects, an unexpected finding that led researchers to develop a more selective, smaller descendant peptide, ultimately approved as the drug bremelanotide.
Melanotan II itself was never developed into an approved drug and never completed the clinical trial and regulatory process that its more selective descendant went through. It nonetheless became widely sold on the gray market as an injectable tanning product, marketed for cosmetic skin darkening despite lacking approval for that or any other use, a use case its original University of Arizona developers did not pursue commercially.
Mechanism (plain language)
Activates melanocortin receptors broadly (MC1R for pigmentation, MC3R/MC4R centrally for erection and desire pathways), unlike bremelanotide's narrower receptor profile.
How it works
Melanotan II activates melanocortin receptors across the body without much selectivity between subtypes. Through MC1R, the receptor found on melanocytes in the skin, it stimulates the production of eumelanin, the pigment responsible for darker skin tones, producing a tan-like darkening independent of sun exposure, which is the basis for its unapproved use as a tanning injection.
Because it also activates MC3R and MC4R in the central nervous system at the same time, it produces effects unrelated to pigmentation, most notably on sexual arousal and desire, along with effects on appetite that researchers have studied separately in the context of energy balance. Animal research localized the pro-erectile effect specifically to central and spinal melanocortin receptor activity rather than to local blood flow changes, mechanistically distinguishing it from erectile dysfunction drugs that act on blood vessels directly. This broad, non-selective receptor activity is precisely what distinguishes Melanotan II from bremelanotide, which was engineered afterward specifically to narrow that activity toward the desire-related receptors and away from the pigmentation-related one.
What research suggests
Small double-blind, placebo-controlled crossover studies in men with both organic and psychogenic erectile dysfunction found Melanotan II reliably induced erections and increased self-reported sexual desire compared with placebo, using real-time monitoring (RigiScan).
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Skin pigmentation and tanning
Its activation of MC1R reliably darkens skin pigmentation independent of UV exposure, which is the basis for its unapproved gray-market use as an injectable tanning product, though this is not a studied or approved therapeutic benefit.
Erectile response in clinical studies
A double-blind, placebo-controlled crossover study in men with both organic and psychogenic erectile dysfunction found Melanotan II reliably induced erections, measured with real-time RigiScan monitoring, compared with placebo.
Increased self-reported sexual desire
The same controlled human studies reported increased self-reported sexual desire alongside the erectile response, the finding that redirected research toward the melanocortin pathway for sexual dysfunction.
Research foundation for an approved successor drug
Its pharmacology directly informed the development of bremelanotide (Vyleesi), the narrower, FDA-approved melanocortin drug for hypoactive sexual desire disorder, giving Melanotan II a genuine, if indirect, place in an approved drug's development history.
Uncertainties & risks
Never approved as a drug; the tanning-injection gray market is unregulated with unknown purity. Nausea and yawning were frequent even in supervised trials, and case reports elsewhere describe pigmented lesions/moles with unsupervised use. Bremelanotide, not Melanotan II, is the version that went through modern regulatory trials.
Melanotan II has never been approved as a drug anywhere and has not gone through the kind of large-scale, modern clinical trial program that its descendant bremelanotide completed. The human data that exists is limited to smaller, earlier-stage studies focused mainly on erectile function rather than the tanning use it is actually sold for, so the gray-market tanning use in particular rests on essentially no controlled human safety or efficacy data specific to that application. The unregulated tanning-injection market that has grown up around Melanotan II carries the same purity and manufacturing concerns as other unregulated research chemicals, and nausea and yawning were common side effects even in the supervised trial settings described above, at doses and monitoring far more careful than typical unsupervised use. Case reports outside formal trials describe darkened or new pigmented moles and lesions with unsupervised use, a concern tied to its broad, non-selective activation of pigmentation pathways, and because it is not manufactured or dosed under any regulatory oversight, individual product quality and actual peptide content cannot be verified. Bremelanotide, not Melanotan II, is the version of this pharmacology that underwent the modern regulatory review and is available as an approved medicine.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.